Four lawmakers announced March 7 that they are rewriting the psychedelic treatment bill. Rep. Nancy MaysAnd Rep. Madeline DeanAnd Senator Cory BookerAnd Senator Rand Paul presented the The Penetration Therapeutics Actan updated bill that would amend the Controlled Substances Act (CSA) and open access to substances such as MDMA or psilocybin to medical patients.
“Evolving therapies give us the opportunity to improve the lives of all those who suffer from treatment-resistant mental illnesses. It is our duty to ensure that veterans have access to every potential treatment option that shows promise, including therapies with the help of MDMA and psilocybin,” Mace said in a press release. “This legislation will remove bureaucratic hurdles that have impeded critical research and the compassionate use of treatments that could save lives.”
if passed, Law amendment The CSA’s definition of “currently accepted medical use with strict restrictions” to include “active ingredients for treatments that receive breakthrough therapy approval by the FDA or expanded access approval.” In effect, this would allow the DEA to move some “cutting edge therapies” from Schedule I substances into a Schedule II category, which is less restrictive when it comes to research and studies on compassionate medical use.
“According to recent studies, some Schedule I substances such as MDMA and psilocybin could offer significant advances in the treatment of depression, severe PTSD, and addiction,” Booker said. “This bill will eliminate unreasonably onerous rules and regulations that delay or prevent researchers from studying these advanced mental health treatments, and will provide access to these promising therapies to eligible patients in urgent need of care.”
the The most recent copy of the invoice It includes a section stating that substances that pass from Schedule I to Schedule II may be returned to Schedule I “if the drug is no longer a current acceptable medical use with strict restrictions and the Secretary of Health and Human Services recommends that the Attorney General control the drug in Schedule I according to subsections,” it states Text. In this case, the attorney general will act within 90 days of receiving a letter from the secretary to issue a temporary final rule.
Originally, he introduced Booker and Paul The previous version of this law in November 2022But she made no progress in the Senate. Previously, Booker and Paul also presented “Right to tryLegislation in July 2022. “As a physician, I know how important the right to try is to patients facing a life-threatening condition,” Paul said last year. “Unfortunately, the federal bureaucracy continues to block patients who seek to use Schedule I drugs under the right to try. I am proud to have led this bipartisan legislation with Senator Booker that will get the government out of the way and give physicians more resources to help patients.”
And the growing support for the drug as a medicine provides evidence that patients can benefit from it. A press release from Mace states that more than 40 organizations have come out in support of the new bill, such as Veteran Mental Health Leadership AllianceAnd Reason for hopeAnd American Special Operations Association. It is also important to note that the Australian government It was announced as recently as February 3 that MDMA and psilocybin would be rescheduled to allow doctors to prescribe those substances to patients suffering from post-traumatic stress disorder (PTSD) or treatment-resistant depression.
Many patients can benefit from access to MDMA and psilocybin therapies, especially veterans. Other efforts are currently underway to help advance cannabis research efforts as a way to treat post-traumatic stress disorder and chronic pain in military veterans. Senate Bill 326or the VA Medical Cannabis Research Act, requires that the U.S. Department of Veterans Affairs (VA) conduct research and report findings to Congress regarding its therapeutic value.